Accéder au contenu
Merck
Toutes les photos(1)

Documents

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

Synonyme(s) :

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H8F2N4O
Numéro CAS:
106308-44-5
Poids moléculaire :
238.19
Numéro MDL:
MFCD00865314
Code UNSPSC :
12352200
ID de substance PubChem :
24724595
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white

Solubilité

DMSO: 9 mg/mL

Auteur

Novartis

Température de stockage

−20°C

Chaîne SMILES 

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

Clé InChI

POGQSBRIGCQNEG-UHFFFAOYSA-N

Informations sur le gène

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Actions biochimiques/physiologiques

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Caractéristiques et avantages

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Implications diagnostiques

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H336,H351,H361fd

Classification des risques

Carc. 2 - Repr. 2 - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

Lacosamide solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamide solution

vibrant-m

Y0001982

Lacosamide

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Teriflunomide ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomide

Retigabine analytical standard

Supelco

90221

Retigabine

Gabapentin solid

Sigma-Aldrich

G154

Gabapentin

Streptavidine Sepharose™ haute performance Cytiva 17-5113-01, pack of 5 mL

GE17-5113-01

Streptavidine Sepharose™ haute performance

Shin Hye Kim et al.
Seizure, 21(4), 288-291 (2012-03-17)
To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included
M Häusler et al.
Neuropediatrics, 42(1), 28-29 (2011-05-11)
Epilepsy with myoclonic absences (EMA) is a rare epileptic syndrome with frequently poor response to antiepileptic treatment. Rufinamide (RUF) is a relatively new EMEA- and FDA-approved anticonvulsant licensed as an orphan drug for the adjunctive treatment of patients with Lennox-Gastaut
K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Iolanda Mazzucchelli et al.
Analytical and bioanalytical chemistry, 401(3), 1013-1021 (2011-06-07)
The development of a simple and rapid high-performance liquid chromatography (HPLC) method for the determination of the new antiepileptic drug rufinamide (RFN) in human plasma and saliva is reported. Samples (250 μl) are alkalinized with ammonium hydroxide (pH 9.25) and
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique